We synthesized a fluorescence conjugate and modified magnetite-gold nanoparticles carrying prostate specific membrane antigen (PSMA) as the ligand. Analysis of their binding to human prostate cancer cell lines PC-3 (PSMA–) and LNCaP (PSMA+) showed selective interaction of the synthesized conjugate and modified nanoparticles with LNCaP cells. These findings suggest that these nanoparticles can be used in tissue-specific magnetic-resonance imaging.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Colombatti M, Grasso S, Porzia A, Fracasso G, Scupoli MT, Cingarlini S, Poffe O, Naim HY, Heine M, Tridente G, Mainiero F, Ramarli D. The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS One. 2009;4(2):e4608.
Etame AB, Diaz RJ, O’Reilly MA, Smith CA, Mainprize TG, Hynynen K, Rutka JT. Enhanced delivery of gold nanoparticles with therapeutic potential into the brain using MRI-guided focused ultrasound. Nanomedicine 2012;8(7):1133-1142.
Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 2004;22(8):969-976.
Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, Severens JL, Barentsz JO. The diagnostic ac-curacy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin. Radiol. 2008;63(4):387-395.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J. Clin. 201;61(2):69-90.
Kireev I, Lakonishok M, Liu W, Joshi VN, Powell R, Belmont AS. In vivo immunogold labeling confirms large-scale chromatin folding motifs. Nat. Methods 2008;5(4):311-313.
Kularatne SA, Wang K, Santhapuram HK, Low PS. Prostatespecific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol. Pharm. 2009;6(3):780-789.
Linn MM, Ball RA, Maradiegue A. Prostate-specific antigen screening: friend or foe? Urol. Nurs. 2007;27(6):481-489.
Nakajima T, Mitsunaga M, Bander NH, Heston WD, Choyke PL, Kobayashi H. Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibodyindocyanine green (ICG) conjugate. Bioconjug. Chem. 2011;22(8):1700-1705.
Shibutani ST, Yoshimori T. A current perspective of autophagosome biogenesis. Cell Res. 2014;24(1):58-68.
Tse BW, Cowin GJ, Soekmadji C, Jovanovic L, Vasireddy RS, Ling MT, Khatri A, Liu T, Thierry B, Russell PJ. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Nanomedicine (Lond). 2015;10(3):375-386.
Yigit MV, Moore A, Medarova Z. Magnetic nanoparticles for cancer diagnosis and therapy. Pharm. Res. 2012;29(5):1180-1188.
Yu H, Chen M, Rice PM, Wang SX, White RL, Sun S. Dumbbell-like bifunctional Au-Fe3O4 nanoparticles. Nano Lett. 2005;5(2):379-382.
Zhang H. Quantum dot-A10 RNA aptamer-doxorubicin conjugate. MICAD. 2008, Aug 25.
Zhu Y, Sun Y, Chen Y, Liu W, Jiang J, Guan W, Zhang Z, Duan Y. In vivo molecular MRI imaging of prostate cancer by targeting PSMA with polypeptide-labeled superparamagnetic iron oxide nanoparticles. Int. J. Mol. Sci. 2015;16(5):9573-9587.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 161, No. 5, pp. 651-655, May, 2016
Rights and permissions
About this article
Cite this article
Machulkin, A.E., Garanina, A.S., Zhironkina, O.A. et al. Nanohybride Materials Based on Magnetite-Gold Nanoparticles for Diagnostics of Prostate Cancer: Synthesis and In Vitro Testing. Bull Exp Biol Med 161, 706–710 (2016). https://doi.org/10.1007/s10517-016-3490-3
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-016-3490-3